Related Experiment Videos
Tobramycin: in vitro and clinical evaluation in 30 patients
The American Journal of the Medical Sciences
|May 1, 1976
Summary
Intramuscular tobramycin effectively treated gram-negative bacillary infections in 30 patients. The antibiotic showed particular efficacy against Pseudomonas aeruginosa, achieving clinical cures in over half of the participants.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Gram-negative bacillary infections pose significant therapeutic challenges.
- Aminoglycosides, such as tobramycin, are crucial for treating serious gram-negative infections.
- Understanding tobramycin's efficacy and spectrum is vital for clinical application.
Purpose of the Study:
- To evaluate the clinical effectiveness of intramuscular tobramycin.
- To assess tobramycin's activity against various gram-negative bacilli.
- To determine cure rates in patients with diverse infections.
Main Methods:
- Clinical trial involving 30 patients with infections caused by gram-negative bacilli.
- In vitro susceptibility testing of bacterial isolates to tobramycin.
- Assessment of clinical and bacteriologic outcomes post-treatment.
Main Results:
- Tobramycin demonstrated median sensitivity of 0.62 µg/ml against Pseudomonas aeruginosa.
- Activity against Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and Enterobacter species was observed, with MICs ≤ 2.5 µg/ml.
- Clinical and bacteriologic cures were achieved in 53% of patients; 81% of urinary tract infections were cured.
- Satisfactory clinical responses were noted in 9 of 14 patients without bacteriologic cure.
Conclusions:
- Intramuscular tobramycin is effective for selected gram-negative bacillary infections.
- The antibiotic shows particular promise for treating Pseudomonas aeruginosa infections.
- Tobramycin offers a valuable therapeutic option, especially for urinary tract infections.